Cure8 trial brief
Many people with Crohn's disease remain on oral aminosalicylates despite uncertainty about their benefit in CD. This trial directly tested whether stopping 5-ASA is acceptably safe compared with continuing it for maintaining remission over 24 months.
Adults with Crohn's disease on 5-ASA therapy; gastroenterologists and IBD clinicians; researchers studying medication de-escalation in IBD.
This interventional, open-label study randomized adults with Crohn's disease in clinical remission who had been taking any oral 5-ASA for at least 6 months to either continue the same 5-ASA regimen or discontinue it. The primary registered outcome was CD-related complications at 2 years (surgery, hospitalization, or other complication).
Eligibility excluded active perianal or fistulizing disease, recent major bowel surgery, recent steroid use, and other conditions that could interfere with participation.
This record is a trial registry entry (Phase 4, completed) and provides design and eligibility details but does not include outcome results in the provided text. Interpret any clinical implications only after reviewing peer-reviewed trial results or guideline updates.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study documents shifting real-world prescribing for newly diagnosed IBD in Germany, with more biologic use and less mesalazine/thiopurine in recent years — changes that could affect treatment expectations and access.
This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...
This study tests a common clinical question: whether increasing vedolizumab frequency helps patients who show no endoscopic response after 6 months. The results suggest intensification raised drug levels but did not...
